SCM
TRAW icon

Squadron Capital Management’s Traws Pharma TRAW Stock Holding History

Squadron Capital Management’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-511,714
Closed -$936K – 57
2026
Q1 		$936K Sell
511,714
-201,826
-28% -$379K 0.34% 32
2025
Q4 		$806K Buy
+713,540
New +$1.59M 0.34% 31

Other funds holding TRAW

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Squadron Capital Management's TRAW Position: Q2 2026 in Review

Squadron Capital Management sold out of Traws Pharma (TRAW) in Q2 2026, closing a stake of 511,714 shares — an estimated $936K sold.

Squadron Capital Management first reported a position in TRAW in Q4 2025 and held it in 2 quarters. The position peaked at $936K in Q1 2026. 35 funds tracked by Wall St. Rank hold TRAW as of Q2 2026.

  • Squadron Capital Management reported no remaining Traws Pharma position as of Q2 2026 after selling out during the quarter.
  • Squadron Capital Management sold 511,714 Traws Pharma shares in Q2 2026, an estimated $936K.
  • Squadron Capital Management first reported a position in Traws Pharma in Q4 2025 and held it in 2 quarters.
  • Squadron Capital Management's Traws Pharma position peaked at $936K in Q1 2026.
  • 35 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.